Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor

Published:2016-10 Issue:5 Volume:16 Page:344-348
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Tiwari Shruti Rakesh^ORCID,Mishra Prasun,Abraham Jame

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets;Clynes;Nat Med,2000

4. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu;Cooley;Exp Hematol,1999

5. Targeting HER proteins in cancer therapy and the role of the non-target HER3;Hsieh;Br J Cancer,2007

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neratinib safety evaluation: real-world adverse event analysis from the FAERS database;Frontiers in Pharmacology;2024-09-13

2. Design, Synthesis, Molecular Docking, and in vitro Cytotoxicity Studies of Marine Natural Product Herdmanine Derivatives as Multitarget Inhibitor for EGFR and HER2 Breast Cancer Proteins;ChemistrySelect;2024-09-09

3. A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases;Journal of Neuro-Oncology;2024-07-10

4. Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance;International Journal of Molecular Sciences;2024-01-25

5. Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer;Cancer Control;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3